link to webcast lien
Category: Webcast
License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Invir.IO™ Platform
License Option Exercise by AstraZeneca
TG4050, First positive clinical data from Phase I clinical trials
link to webcast
Half-Year results 2021 & Business Update
lien
2021 Full-year results and business update
link to webcast
Full Year Results 2020, Business Update & Update on the clinical development plan of TG4001
Link to the webcast
Results from Phase 1b/2 Study of TG4001 with Avelumab in Advanced HPV-Positive Cancers
https://channel.royalcast.com/webcast/transgene/20200722_1/
First efficacy results of TG4001+avelumab in HPV16-positive cancers
https://channel.royalcast.com/webcast/transgene/20191003_1/
Transgene and Tasly Biopharmaceuticals conclude strategic agreements for the rights of TG6002 and TG1050 in Greater China
Webcast
